IIT2020-02-Gong-GlutaPanc: Phase I Trial of First-line L-glutamine with Gemcitabine and Nab-paclitaxel in Advanced Pancreatic Cancer (GlutaPanc)
Latest Information Update: 06 Nov 2024
Price :
$35 *
At a glance
- Drugs Gemcitabine (Primary) ; Glutamine (Primary) ; Paclitaxel (Primary)
- Indications Pancreatic cancer
- Focus Adverse reactions
- Acronyms GlutaPanc
- 14 Jul 2023 Planned End Date changed from 1 Jan 2024 to 6 Jul 2025.
- 14 Jul 2023 Status changed from recruiting to active, no longer recruiting.
- 16 Jan 2023 Planned primary completion date changed from 1 Dec 2022 to 1 Jun 2023.